文献速递甲状腺疾病

临床医生对甲状腺结节超声特征分类的一致性:两项内分泌学会调查

Clinician Agreement on the Classification of Thyroid Nodules Ultrasound Features: A Survey of 2 Endocrine Societies.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

该研究调查内分泌学会和拉丁美洲甲状腺学会成员对10例甲状腺结节超声特征(成分、回声、形状、边缘、强回声灶)的判读,并按ACR-TIRADS框架计算癌症风险分类。共纳入144名参与者,ACR-TIRADS风险分类的总体一致性为AC1 0.29(95%CI 0.13-0.45),各超声特征的一致性高低不一,提示甲状腺结节风险分层广泛实施面临挑战。

要点

  • 144名临床医生对10例甲状腺结节超声特征判读,ACR-TIRADS风险分类总体一致性AC1为0.29。
  • 无强回声灶和成分的一致性为中等(AC1分别为0.53和0.54)。
  • 边缘、回声和形状评估的一致性较低(AC1分别为0.24、0.34和0.42)。

核心结论

  • 研究观察到临床医生对ACR-TIRADS风险分类及单个超声特征的判读存在高度变异,可能对甲状腺结节风险分层的广泛实施构成挑战。

研究设计与样本

  • 调查内分泌学会和拉丁美洲甲状腺学会成员,评估10例甲状腺结节病例的超声特征判读并按ACR-TIRADS框架计算癌症风险分类,共纳入144名参与者,大多为内分泌科医生。

主要发现

  • 无强回声灶的一致性为中等(AC1 0.53,95%CI 0.24-0.81),成分的一致性为中等(AC1 0.54,95%CI 0.36-0.71)。
  • 边缘的一致性较低(AC1 0.24,95%CI 0.15-0.33),回声的一致性较低(AC1 0.34,95%CI 0.22-0.46),形状评估的一致性较低(AC1 0.42,95%CI 0.13-0.70)。
  • ACR-TIRADS评估的总体一致性为AC1 0.29(95%CI 0.13-0.45)。
  • 亚组分析中ACR-TIRADS的AC1相似。

关键数值与推荐

  • 无强回声灶:AC1 0.53(95%CI 0.24-0.81)。
  • 成分:AC1 0.54(95%CI 0.36-0.71)。
  • 边缘:AC1 0.24(95%CI 0.15-0.33)。
  • 回声:AC1 0.34(95%CI 0.22-0.46)。
  • 形状:AC1 0.42(95%CI 0.13-0.70)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Thyroid nodule risk stratification allows clinicians to standardize the evaluation of thyroid cancer risk according to ultrasound features. OBJECTIVE: To evaluate interrater agreement among clinicians assessing thyroid nodules ultrasound features and thyroid cancer risk categories. DESIGN, SETTING, AND PARTICIPANTS: We surveyed Endocrine Society and Latin American Thyroid Society members to assess their interpretation of composition, echogenicity, shape, margins, and presence of echogenic foci of 10 thyroid nodule cases. The risk category for thyroid cancer was calculated following the American College of Radiology-Thyroid Imaging Reporting & Data System (ACR-TIRADS) framework from individual responses. MAIN OUTCOMES AND MEASURES: We used descriptive statistics and Gwet's agreement coefficient (AC1) to assess the primary outcome of interrater agreement for ACR-TIRADS risk category. As secondary outcomes, the interrater agreement for individual features and a subgroup analysis of interrater agreement for the ACR-TIRADS category were performed (ultrasound reporting system, type of practice, and number of monthly appraisals). RESULTS: A total of 144 participants were included, mostly endocrinologists. There was moderate level of agreement for the absence of echogenic foci (AC1 0.53, 95% CI 0.24-0.81) and composition (AC1 0.54, 95% CI 0.36-0.71). The agreement for margins (AC1 0.24, 95% CI 0.15-0.33), echogenicity (AC1 0.34, 95% CI 0.22-0.46), and shape assessment (AC1 0.42, 95% CI 0.13-0.70) was lower. The overall agreement for ACR-TIRADS assessment was AC1 0.29, (95% CI 0.13-0.45). The AC1 of ACR-TIRADS among subgroups was similar. CONCLUSIONS: This study found high variation of judgments about ACR-TIRADS risk category and individual features, which poses a potential challenge for the widescale implementation of thyroid nodule risk stratification.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Burgos N, Zhao J, Brito JP, et al. Clinician Agreement on the Classification of Thyroid Nodules Ultrasound Features: A Survey of 2 Endocrine Societies. J Clin Endocrinol Metab. 2022. PMID: 35521676. doi:10.1210/clinem/dgac279

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。